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Angiotensin converting enzyme inhibitors (ACEIs) have been
shown to be effective in the treatment of dialysis patients with
high blood pressure, however, they also have been associated with
anaphylactoid reactions at the start of dialysis, when they have
been used concomitantly with AN69 membranes. A multicenter,
open six-month study was designed to test the tolerability and
efficacy of losartan as antihypertensive in patients under hemodi-
alysis (HD), with particular emphasis on the appearance of
anaphylactoid reactions. HD patients with systolic blood pressure
(SBP) levels $ 140 and/or diastolic blood pressure (DBP) $ 90
mm Hg, previously nontreated, treated but uncontrolled, or
treated with a poor tolerability, were included. The study per-
formed three controls: baseline, at month 3, and at study comple-
tion. DBP and SBP levels were measured on the six HD sessions
previous to the three visits in addition to biochemical and
hematology measurements. Four hundred and six patients were
included. The mean age was 55 years, 42% were women, and
23.6% of the patients were dialyzed with AN69 membranes. There
was a significant reduction in pre- and postdialysis SBP and DBP
at three and six months. Fifteen patients discontinued the study
due to adverse reactions related to losartan, and in seven of them
the adverse reaction was hypotension. Only two patients have
reported a possible anaphylactoid reaction on treatment with
AN69, in one of them the HD session had to be stopped and
losartan was discontinued. On the contrary, nine patients with a
history of previous anaphylactoid reaction, with ACEIs and
AN69, have not shown this complication with losartan and AN69.
We conclude that losartan is a well tolerated antihypertensive by
HD patients, with a very low incidence of adverse reactions, and
a lower prevalence of anaphylactoid reactions than those detected
with ACEIs and AN69.
The main causes of mortality among patients with
chronic renal failure under hemodialysis are cardiovascular
complications, and high blood pressure (HBP) is one of its
primary risk factors for cardiac involvement [1]. Volume
reduction by decreasing dry weight normalizes blood pres-
sure (BP) in some cases, but a percentage of patients
ranging from 58% to 83% require medication to control BP
[2].
Angiotensin-converting enzyme inhibitors (ACEIs) may
be effective in hemodialysis hypertensive patients, even in
states of low renin production such as that found in
anephric patients. However, ACEIs have also been shown
to cause significant side effects, most commonly hypersen-
sitivity reactions, hyperkalemia and neutropenia. In 1990,
anaphylactoid reactions (AR) were described in ACEI-
treated patients under dialysis with polyacrylonitrile mem-
branes (AN69) [3]. Similar reactions have occasionally
been reported in dialysis patients who use polysulfone and
other synthetic membranes [4].
In a literature review involving 1087 dialysis subjects, in
a subgroup of 72 AN69-dialyzed patients simultaneously
treated with ACEIs, 41 (57%) showed AR, while none of
the 71 patients under dialysis with other membranes and
ACEIs experienced such a complication. Only 2 out of 519
patients dialyzed with AN69 not receiving ACEIs (0.4%)
experienced AR [5]. A more recent survey found that the
association of dialysis with AN69 and ACEI treatment was
particularly dangerous for the development of AR, the
prevalence of AR with such association being 7.2%, as
compared to 1.6% in dialysis patients with other synthetic
membranes and treated with ACEIs, and to 3.2% in
patients dialyzed with AN69 not receiving ACEIs [6].
The etiopathogenic mechanism of AR is thought to
consist of a bradykinin release due to the activation of the
Hageman factor by the AN69 membrane, which has a
strong electronegative charge. The final result is the pro-
duction of high amounts of bradykinins a few minutes after
the membrane comes in contact with blood. This has been
shown in vitro [7] in an experimental model of sheep
dialysis [8] and in humans [9].
Losartan, a selective blocker of angiotensin II AT1
receptor, has shown an antihypertensive efficacy similar to
ACEIs, with a low incidence of side effects [10], and well
tolerated by patients with chronic renal failure [11]. To date
losartan has not been reported to influence bradykinin
metabolism, and therefore it seems that an antihyperten-
sive agent blocking the renin-angiotensin system without
increasing bradykinins may be useful for treating HBP in
dialyzed patients. The current study was designed with two
aims: first, to obtain experience on the effectiveness and
tolerance of losartan in a large HD population, and second,
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A six-month, longitudinal, multicenter study was con-
ducted in 66 dialysis centers (see participating centers in
Appendix I). Four hundred and six patients with end-stage
chronic renal disease under HD treatment for more than
one month were included. The selection criteria were:
HBP, defined as a patient having a mean predialysis BP
value over 140/90 in six consecutive dialysis sessions, and
normal BP values under treatment with other antihyper-
tensive agents, which in the opinion of the local investigator
warranted a switch from previous antihypertensive treat-
ment to losartan. Exclusion criteria were a disease with a
life expectancy under six months, age under 18, and preg-
nancy. If the previous antihypertensive treatment included
in ACEI, a three-week washout period was established.
Before starting losartan therapy, both pre- and post-
dialysis BP was recorded during six consecutive dialysis
sessions. BP was measured manually with a mercury col-
umn manometer, systolic blood pressure (SBP) corre-
sponding to the first audible sound and diastolic blood
pressure (DBP) to the last audible sound minus 2 mm Hg.
During that period, occurrence of hypotensive episodes in
dialysis was also registered. A hypotensive episode was
defined as a BP decrease requiring intravenous fluid infu-
sion.
AR was defined by the appearance of at least two of the
following symptoms or signs within the first 15 minutes of
dialysis: a BP decrease greater than 30 mm Hg compared to
predialysis values, a generalized heat sensation; dysesthesia
in fingers, lips or tongue; lip or tongue swelling; dyspnea or
audible wheezing; nausea, vomiting or diarrhea; and angio-
edema or laryngeal edema.
Laboratory tests were performed at baseline, including a
complete blood count, AST, ALT, GGT, alkaline phospha-
tase, ferritin and serum potassium. Clinical information on
hemodialysis schedule, drug treatment and demographic
variables were also recorded.
Losartan treatment was started at a dose of 25 mg/day
and increased after one week to a 50 mg/day dose that was
maintained to the end of the study. Patients were reas-
sessed after three and six months (end of study) with the
same protocol as for the pre-treatment asessment. If after
four weeks on losartan therapy BP remained uncontrolled,
a second or third antihypertensive drug (except ACEIs)
could be added. The protocol was approved by the Ethics
Committee for Clinical Investigation of the Galdakao
Hospital, which acted as coordinating center.
Statistical analysis
A paired Student’s t-test was used to compare quantita-
tive variables. Values obtained at six and three months after
treatment were compared to those obtained before treat-
ment. For non-normal variables, the Wilcoxon test was
used. Similarly, McNemar’s test was used for qualitative
variables in order to compare the percentages obtained at
three and six months with those obtained at baseline. A
value of P , 0.05 was considered significant, and quantita-
tive results were expressed as mean 6 SD.
RESULTS
Patient description
A total of 406 patients started treatment with losartan; 82
(20.2%) of them were dropped out (Table 1). The mean
age was 55.5 6 15 years, ranging from 18 to 85 years; 42%
Fig. 1. Mean values of blood pressure (BP) in hemodialysis patients, at baseline, three and six months. *P , 0.05 compared to baseline.
Saracho et al: Evaluation of losartan in hemodialysisS-126
of them were women. In most of them (93%), bicarbonate
was used as a buffer. The dialysis techniques used were
hemofiltration (1%), hemodiafiltration (11%) and conven-
tional hemodialysis (88%). Reverse osmosis was used as
water treatment system in all patients. Before starting
treatment, 76% of the patients were receiving another
antihypertensive agent; 33% and 60% of subjects included
in the study were taking an ACEI or a calcium antagonist,
respectively. Once treatment began, 75% of patients used
losartan as monotherapy.
Nine patients had suffered anaphylactoid reactions when
they were dialyzed with an AN69 filter in association with
ACEI treatment.
Antihypertensive efficacy
A significant decrease was seen in the mean systolic and
diastolic BP, before and after dialysis, at three and six
months compared to baseline (Table 2). There was also an
increase in the percentage of patients with BP under
140/90, which was more marked when limits were estab-
lished at 160/90. There were no significant changes in the
average weight gain when comparing baseline to three and
six-month conditions.
At baseline 75% of patients started losartan as mono-
therapy, and at the end of the study 56% remained in
monotherapy with this drug. The other antihypertensive
drugs used were: Ca channel blockers, beta-blockers and
alpha adrenergic antagonists.
Tolerance to losartan therapy
A total of 15 patients withdrew from the study due to
adverse reactions related with the drug, a prevalence of
3.7%. The most common treatment-related adverse reac-
tion was hypotension during or after dialysis, found in seven
patients. When hypotension episodes were analyzed, the
comparison of the number of sessions with hypotension at
baseline versus three and six months after treatment showed
no significant differences, P 5 0.65 and 0.56, respectively.
A significant increase was seen in plasma potassium
levels after losartan treatment (Table 2), however, the
increase was small and no patients had to discontinue
treatment because of it. AST and ALT remained stable
throughout the study, and only a mild transaminase in-
crease, less than twice normal values that was not present in
previous visits, could be seen in five cases after six months
of treatment. Similarly, a mild, nonsignificant increase
occurred in cases of leukopenia. No new cases of throm-
bopenia were detected. There was a significant increase in
hematocrit and hemoglobin levels, without changes in eryth-
ropoietin (EPO) dosage nor ferritin plasma levels (Table 2).
Anaphylactoid reactions
Ninety-six patients were dialyzed with AN69 membrane
throught the study two of them showed one episode of
possible AR meeting the criteria given in the Methods
section. In one case, the reaction consisted of hypotension
13 minutes after HD onset with a generalized heat sensa-
tion, malaise, nausea, vomiting and dysesthesia that was
severe enough to stop HD. In the other case there were
mild subjective symptoms in the first minute of dialysis
session consisting of generalized heat sensation and dyses-
thesia, which did not require the discontinuation of hemo-
dialysis and were not repeated in the next HD sessions
despite the maintenance of treatment with losartan and the
AN69 membrane. None of the cases showed unequivocal
hypersensitivity signs such as edema, bronchospasm, pruri-
tus or skin lesions of urticaria or erythema. If we consider
such cases as AR, we get an AR prevalence in patients
under AN69 dialysis of 2,08%, with an exact 90% confi-
dence interval ranging from 0.37% to 6.4%. By contrast,
nine patients who had shown a previous AR with ACEIs
and AN69 did not experience it again when they were
treated with losartan and dialyzed with the same mem-
brane. Ninety-six patients were dialyzed with polysulfone
membrane throught the study. One of them suffered a
possible AR(1.04%); the staff responsible for the patient
considered that this reaction was not related to the drug and
maintained this treatment without observing further AR.
DISCUSSION
The results of this study support the role of losartan as an
effective antihypertensive drug in HD patients. Losartan
induces a lower number of ARs than ACEIs in subjects
Table 1. Reasons for the drop-outs in this study
No. cases
Adverse reactions related to losartan 15
Adverse reactions not related to losartan
(excluding deaths)
9
Deaths not related to losartan 4
Renal transplant 17
Patient’s own decision 18
Discontinuation of hemodialysis 2
Lost to follow up 2
Decrease of BP to normal values 10
Lack of BP control 5
Table 2. Changes of BP and lab values along the study
Baseline 3 months 6 months
SBP pre-dialysis mm Hg 163 6 16 155 6 15a 152 6 16ab
DBP pre-dialysis mm Hg 88 6 10 84 6 9a 83 6 9a
SBP post-dialysis mm Hg 148 6 18 140 6 19a 139 6 18ab
DBP post-dialysis mm Hg 82 6 9 78 6 10a 77 6 9ab
% BP ,140/90 mm Hg 4 14a 22a
% BP ,160/90 mm Hg 31 56a 60a
Plasma K1 mEq/liter 5.46 6 0.84 5.71 6 0.77a 5.74 6 0.84a
Hemoglobin g/dl 10.17 6 1.64 10.52 6 1.54a 10.67 6 1.64a
Hematocrit % 30.69 6 4.95 31.95 6 4.48a 32.31 6 4.62a
EPO dose IU/kg/week 101 6 58 94 6 59 94 6 64
Ferritin ng/dl 205 6 227 259 6 290 300 6 374
a P , 0.05 compared to baseline
b P , 0.05 compared to 3 months
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dialyzed with AN69 membranes. It must be stressed that
this is the first study conducted with an angiotensin II
antagonist on a large sample of patients with end-stage
chronic renal failure under hemodialysis. However, this is
an uncontrolled study because we believe that it is unethical
to have a control group involving patients treated with
ACEIs and dialyzed with AN69 membranes.
We found a significant decrease in SBP and DBP values
of approximately 10 mm Hg and 5 mm Hg, respectively,
after six months. This decrease is seen both before and
after dialysis, although the post-dialysis absolute values are
lower than those recorded before dialysis. These decreases
are similar to those seen in losartan trials using doses of 50
mg/day conducted in patients with essential arterial hyper-
tension [12]. However, the percentage of patients achieving
good BP control is low, a fact that is possibly explained by
the high BP seen at baseline. Moreover, since almost half of
our patients are over 60 years old, if we consider the limits
160/90 to be good BP control, the percentage increases to
60%. This suggests a predominance of systolic HBP in HD.
It is important to highlight that the better BP control
achieved with losartan does not induce an increase in the
hypotensive episodes during dialysis, although according to
the protocol followed, the drug was also administered on
the same day as the hemodialysis.
The prevalence of adverse effects related to the drug is
generally low, particularly if we take into account that we
are dealing with a special group of patients who are more
liable to develop complications. Overall mortality is low, at
1% after six months, if it is compared with the data in the
Spanish register, which reports an annual mortality on HD
of 14%. This can be due to a biased selection of patients
with a better than average state of health.
Interestingly, losartan causes a mild increase in potas-
sium levels that is clinically not significant (0.3 mEq/liter).
This finding may be explained by the inhibiting action of
losartan on potassium renal excretion. We did not test
residual renal function in our patients, and thus are unable
to verify such a hypothesis. With regards to the effects on
erythropoiesis, it is difficult to explain the increased hemo-
globin and hematocrit levels seen when patients are glo-
bally analyzed.
The mild, nonsignificant increase in cases with high
transaminase levels has also been seen in other losartan
treated patients, however, it was not relevant because no
patient discontinued treatment because of the increase.
Special interest was paid to ARs, and therefore a large
subgroup of patients who were treated with AN69 mem-
branes was enrolled. Two ARs (2.08%) were seen in this
subgroup, which were considered as such although they
were not specific. However, the percentage of ARs with the
association of ACEIs and AN69 found in the literature has
been higher, 57% in one survey and 7.2% in another. Both
percentages exceed the upper confidence level in our study,
which on the other hand is similar to the one published with
AN69 without ACEIs (3.2%). These data suggest that
losartan is not involved in the development of AR. It must
be stressed that a “center effect” has been reported in AR
production, with a prevalence of RA in patients with
ACEIs ranging from 0% to 100%, depending on the
reporting center, and the last series reported an 72%
incidence of ARs in only 7% of the dialysis units. However,
our multicenter study is based on cases from 66 dialysis
units. Therefore, we think that the random error for
estimating the prevalence of ARs caused by the “center
effect” is minimized by the use of such a large number of
centers.
The AR prevalence seen in our patients dialyzed with
polysulfone is similar to that reported in the last series
published to date (1.6%), both in patients treated and not
treated with ACEIs. This is not a surprising finding since
there have been no reports of a greater AR increase
induced by ACEI treatment in patients dialyzed with
polysulfone membranes. This is consistent with the absence
of an AR increase induced by losartan therapy in patients
dialyzed with polysulfone membranes.
Finally, we conclude that losartan is a safe drug that
helps to decrease BP values in HD patients, with no special
incidence of side effects. When starting this drug, a very
slight trend to hyperkalemia must be taken into account.
We have shown in this study that losartan is an adequate
drug for antihypertensive treatment in patients dialyzed
with AN69, since it does not increase the incidence in AR.
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